John Renger
Company: Cerevel Therapeutics
Job title: Ph.D, Chief Scientific Officer
Seminars:
Development of CVL-231 for the Treatment of Psychosis 10:00 am
• CVL-231 was rationally designed as a positive allosteric modulator (PAM) that selectively targets the muscarinic acetylcholine 4 (M4) receptor subtype • Harnessing the anti-psychotic benefit believed to be associated with M4 while minimizing the side effects typically associated with panmuscarinic agonists • Phase 1b data readout • Plans to further evaluate the potential of…Read more
day: Day One
Live Q&A 10:50 am
day: Day One